A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

被引：6
|
作者：
Assouline, Sarit [1 ]
Michaelis, Laura C. [2 ]
Othus, Megan [3 ]
Hay, Annette E. [4 ]
Walter, Roland B. [5 ]
Jacoby, Meagan A. [6 ]
Schroeder, Mark A. [6 ]
Uy, Geoffrey L. [6 ]
Law, Lisa Y. [7 ]
Cheema, Faisal [8 ]
Sweet, Kendra L. [9 ]
Asch, Adam S. [10 ]
Liu, Jijun [11 ]
Moseley, Anna B. [2 ]
Maher, Tracy [12 ]
Kingsbury, Laura L. [12 ]
Fang, Min [5 ]
Radich, Jerald [5 ]
Little, Richard F. [13 ]
Erba, Harry P. [14 ]
机构：
[1] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada
[2] Med Coll Wisconsin, Milwaukee, WI USA
[3] SWOG Stat & Data Management Ctr, Seattle, WA USA
[4] Queens Univ, Kingston, ON, Canada
[5] Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Kaiser Permanente NCAL, Roseville, CA USA
[8] Kaiser Permanente, Santa Clara, CA USA
[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[10] Univ Oklahoma HSC, Oklahoma City, OK USA
[11] Illinois Canc Care Heartland NCORP, Peoria, IL USA
[12] SWOG Data Operat Ctr, Canc Res & Biostat, Seattle, WA USA
[13] Natl Canc Inst, Canc Therapy & Evaluat Program CTEP, Bethesda, MD USA
[14] Duke Univ, Duke Canc Inst, Med Ctr, Durham, NC USA
来源：
LEUKEMIA & LYMPHOMA | 2023年 / 64卷 / 02期
基金：
美国国家卫生研究院;
关键词：
CONVENTIONAL-CARE-REGIMENS; THERAPY;
D O I：
10.1080/10428194.2022.2148212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：473 / 477
页数：5
相关论文
共 50 条
  • [1] PHASE 2 STUDY OF PEVONEDISTAT plus AZACITIDINE vs AZACITIDINE IN PATIENTS WITH HIGH-RISK MYELODISPLASIC SYNDROME (MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) OR ACUTE MYELOID LEUKEMIA (AML) <30% BLAST (NCT02610777)
    Diez, Campelo Maria
    Ades, Lionel
    Watts, Justin
    Radinoff, Atanas
    Arnan, Sangerman Montserrat
    Cerrano, Marco
    Font, Lopez Patricia
    Zeidner, Joshua
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolay
    Fram, Robert J.
    Zhao, Dan
    Bell, Jill
    Friedlander, Sharon
    Faller, Douglas V.
    Sekeres, Mikkael A.
    HAEMATOLOGICA, 2020, 105 : 71 - 72
  • [2] Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial
    Hay, Annette E.
    Assouline, Sarit
    Walter, Roland B.
    Little, Richard F.
    Moseley, Anna
    Gail, Sperling M.
    Im, Annie
    Foran, James M.
    Radich, Jerald P.
    Fang, Min
    Othus, Megan
    Erba, Harry P.
    Michaelis, Laura C.
    BLOOD, 2019, 134
  • [3] Hospitalization rates in elderly, newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) patients treated with azacitidine.
    Ueda, Masumi
    Gupta, Divya
    Caimi, Paolo Fabrizio
    Creger, Richard
    Little, Jane
    William, Basem M.
    Lazarus, Hillard M.
    De Lima, Marcos J. G.
    Cooper, Brenda W.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)
    Kenealy, Melita
    Patton, Nigel
    Filshie, Robin
    Nicol, Andrew
    Ho, Shir-Jing
    Hertzberg, Mark
    Mills, Tony
    Prosser, Ian
    Link, Emma
    Cowan, Linda
    Zannino, Diana
    Seymour, John F.
    LEUKEMIA & LYMPHOMA, 2017, 58 (02) : 298 - 307
  • [5] Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
    Walker, Alison R.
    Bergua Burgues, Juan Miguel
    Montesinos, Pau
    Bixby, Dale
    Guastad Daver, Naval
    Konopleva, Marina
    Patrick Anthony, Stephen
    Tan, Fenlai
    Chen, Yi
    Chen, Yu
    Shen, Yue
    William Burke, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
  • [7] A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117
    Sekeres, Mikkael A.
    Othus, Megan
    List, Alan F.
    Odenike, Olatoyosi
    Stone, Richard M.
    Gore, Steven D.
    Litzow, Mark R.
    Buckstein, Rena
    Velasco, Mario R.
    Gaur, Rakesh
    Atallah, Ehab
    Attar, Eyal
    Appelbaum, Frederick R.
    Erba, Harry P.
    BLOOD, 2014, 124 (21)
  • [8] A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Daver, Naval
    Jabbour, Elias
    Kadia, Tapan
    Borthakur, Gautam
    Konopleva, Marina
    Pemmaraju, Naveen
    Yang, Hui
    Wei, Yue
    Wierda, William G.
    Bueso-Ramos, Carlos E.
    Patel, Keyur P.
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
  • [9] A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)
    Palmisiano, Neil
    Jeschke, Grace
    Wilde, Lindsay
    Leiby, Benjamin E.
    Alpdogan, Onder
    Carabasi, Matthew
    Filicko-O'Hara, Joanne
    Gaballa, Sameh
    Grosso, Dolores
    Klumpp, Thomas R.
    Outschoorn, Ubaldo Martinez
    Wagner, John L.
    Carroll, Martin
    Porcu, Pierluigi
    Flomenberg, Neal
    Perl, Alexander E.
    Kasner, Margaret
    BLOOD, 2017, 130
  • [10] Phase I study of volasertib combined with azacitidine in patients with previously untreated, high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) ineligible for high-intensity therapy
    Platzbecker, Uwe
    Scherres, Winrich
    Guo, Zhenchao
    Calvo, Roser
    Germing, Ulrich
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S233 - S233
12345